1-3 of 3
Marco Righi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Human CD34 + cells engineered to express membrane-bound tumor necrosis factor–related apoptosis-inducing ligand target both tumor cells and tumor vasculature

Cristiana Lavazza, Carmelo Carlo-Stella, Arianna Giacomini, Loredana Cleris, Marco Righi, Daniela Sia, Massimo Di Nicola, Michele Magni, Paolo Longoni, Marco Milanesi, Maura Francolini, Annunziata Gloghini, Antonino Carbone, Franca Formelli, Alessandro M. Gianni
Journal: Blood
Blood (2010) 115 (11): 2231–2240.
https://doi.org/10.1182/blood-2009-08-239632
Published: 2010
Includes: Supplemental data
Journal Articles

Preclinical Rationale for the Use of the Multikinase Inhibitor Sorafenib in the Treatment of Human Lymphomas

Carmelo Carlo-Stella, MD, Cristiana Lavazza, PhD, Arianna Giacomini, PhD, Loredana Cleris, Daniela Sia, PhD, Paolo Longoni, Marco Milanesi, Michele Magni, MD, Massimo Di Nicola, MD, Annunziata Gloghini, PhD, Antonino Carbone, MD, Marco Righi, MD, Franca Formelli, PhD, Alessandro M. Gianni, MD
Journal: Blood
Blood (2008) 112 (11): 2605.
https://doi.org/10.1182/blood.V112.11.2605.2605
Published: 2008
Journal Articles

Human CD34+ Cells Expressing Membrane-Bound Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Exert a Potent Anti-Lymphoma Effects by Targeting Tumor Vasculature.

Carmelo Carlo-Stella, MD, Cristiana Lavazza, Arianna Giacomini, Daniela Sia, Loredana Cleris, Massimo Di Nicola, M.D., Paolo Longoni, Marco Milanesi, Michele Magni, M.D., Marco Righi, M.D., Maura Francolini, Annunziata Gloghini, Anna Guidetti, M.D., Antonino Carbone, M.D., Alessandro M. Gianni, M.D.
Journal: Blood
Blood (2007) 110 (11): 527.
https://doi.org/10.1182/blood.V110.11.527.527
Published: 2007